Yaron-Barir, Tomer M. http://orcid.org/0000-0001-6574-7314
Joughin, Brian A. http://orcid.org/0000-0003-1022-9450
Huntsman, Emily M.
Kerelsky, Alexander
Cizin, Daniel M.
Cohen, Benjamin M.
Regev, Amit
Song, Junho
Vasan, Neil http://orcid.org/0000-0003-1779-484X
Lin, Ting-Yu
Orozco, Jose M.
Schoenherr, Christina http://orcid.org/0000-0002-0983-6168
Sagum, Cari
Bedford, Mark T. http://orcid.org/0000-0002-8899-1050
Wynn, R. Max http://orcid.org/0000-0002-1879-2136
Tso, Shih-Chia
Chuang, David T.
Li, Lei
Li, Shawn S.-C. http://orcid.org/0000-0003-3610-9035
Creixell, Pau
Krismer, Konstantin http://orcid.org/0000-0001-8994-3416
Takegami, Mina http://orcid.org/0000-0002-3744-1577
Lee, Harin
Zhang, Bin
Lu, Jingyi
Cossentino, Ian http://orcid.org/0000-0002-1179-2045
Landry, Sean D.
Uduman, Mohamed
Blenis, John http://orcid.org/0000-0003-3622-2337
Elemento, Olivier http://orcid.org/0000-0002-8061-9617
Frame, Margaret C. http://orcid.org/0000-0001-5882-1942
Hornbeck, Peter V.
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Turk, Benjamin E. http://orcid.org/0000-0001-9275-4069
Yaffe, Michael B. http://orcid.org/0000-0002-9547-3251
Johnson, Jared L. http://orcid.org/0000-0003-1802-6527
Article History
Received: 24 August 2023
Accepted: 10 April 2024
First Online: 8 May 2024
Competing interests
: L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for PI3K-associated disease or disorder, and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment; is a co-founder and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. J.L.J. has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. T.M.Y.-B. is a co-founder of DeStroke. N.V. reports consulting activities for Novartis and is on the scientific advisory board of Heligenics. O.E. is a founder and equity holder of Volastra Therapeutics and OneThree Biotech; is a member of the scientific advisory board of Owkin, Freenome, Genetic Intelligence, Acuamark and Champions Oncology; and receives research support from Eli Lilly, Janssen and Sanofi. M.T.B. is the co-founder of EpiCypher. The other authors declare no competing interests.